Cargando…
Doxycycline directly targets PAR1 to suppress tumor progression
Doxycycline have been reported to exert anti-cancer activity and have been assessed as anti-cancer agents in clinical trials. However, the direct targets of doxycycline in cancer cells remain unclear. In this study, we used a chemical proteomics approach to identify the Protease-activated receptor 1...
Autores principales: | Zhong, Weilong, Chen, Shuang, Zhang, Qiang, Xiao, Ting, Qin, Yuan, Gu, Ju, Sun, Bo, Liu, Yanrong, Jing, Xiangyan, Hu, Xuejiao, Zhang, Peng, Zhou, Honggang, Sun, Tao, Yang, Cheng |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Impact Journals LLC
2017
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5370004/ https://www.ncbi.nlm.nih.gov/pubmed/28187433 http://dx.doi.org/10.18632/oncotarget.15166 |
Ejemplares similares
-
Doxycycline inhibits breast cancer EMT and metastasis through PAR-1/NF-κB/miR-17/E-cadherin pathway
por: Zhong, Weilong, et al.
Publicado: (2017) -
Doxycycline reverses epithelial-to-mesenchymal transition and suppresses the proliferation and metastasis of lung cancer cells
por: Qin, Yuan, et al.
Publicado: (2015) -
6-Gingerol stabilized the p-VEGFR2/VE-cadherin/β-catenin/actin complex promotes microvessel normalization and suppresses tumor progression
por: Zhong, Weilong, et al.
Publicado: (2019) -
Novel Podophyllotoxin Derivatives as Partial PPARγ Agonists and their Effects on Insulin Resistance and Type 2 Diabetes
por: Zhang, Xiangming, et al.
Publicado: (2016) -
Problems and Solutions in Click Chemistry Applied to Drug Probes
por: Zhong, Weilong, et al.
Publicado: (2016)